核小体结合蛋白（NSBP1）又名HMGN5，属于高迁移族核小体结合蛋白家族成员，对染色质重塑调节发挥重要的作用。NSBP1通过与组蛋白H1竞争结合核小体抑制H1与染色质的结合，调节染色质重塑，促进异染色质向常染色质转变。常染色质因其易于基因转录表达、DNA复制和DNA损伤及修复，与肿瘤发生发展密切相关。本课题组首次发现NSBP1在前列腺癌组织中高表达，并在后续系列研究中证实NSBP1具有很强的促进前列腺癌细胞增殖浸润和抑制凋亡的作用，且与癌细胞对放化疗敏感性相关，具有很高的临床应用价值。然而NSBP1如何发挥其促癌作用以及该作用是否与其染色质重塑功能相关均不清楚，这成为了以NSBP1为靶点的前列腺癌治疗转化研究的瓶颈。本项目拟通过分子生物学手段解析NSBP1促进前列腺癌发生发展的作用与其染色质重塑功能的关系，为以NSBP1为靶点的前列腺癌精准治疗提供理论依据。

Nucleosomal binding protein 1 (NSBP1), also known as HMGN5, is a member of high-mobility group nucleosome binding domain (HMGN) family and plays an important role in chromatin remodeling. NSBP1 promotes chromatin decondensation and conversion from heterochromatin to euchromatin by competing with histone H1 in nucleosome binding. As its loosen structure, euchromatin is prone to interacting with trans-acting factor and promotes DNA replication and transcription. NSBP1 is overexpressed in prostate cancer tissue, which was first identified by our group, and our latter investigation proved that NSBP1 is involved in promoting prostate cancer cells proliferation, anti-apoptosis and invasion. The latest studies shows that the expression of NSBP1 relates to radiotherapy insensitivity of prostate cancer cells, suggesting the high clinical application value of NSBP1. Nevertheless, the mechanism through which NSBP1 promotes prostate cancer initiation and development and whether it is related to chromatin remodeling are still unknown. It heavily hinders the research on applying NSBP1 into prostate cancer treatments. This project aims at determining the relationship between tumor promotion and chromatin remodeling functions of NSBP1 through molecular and cellular biologic technology. The accomplishment of this project will provide a theoretical basis for personalized therapy on prostate cancer.